Riparian Pharmaceuticals Announces Agreements with Pfizer for Novel Cardiovascular Programs
As part of the research agreement, Pfizer will support Riparian’s efforts to discover further drug targets leading to…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
20 Jul 23
As part of the research agreement, Pfizer will support Riparian’s efforts to discover further drug targets leading to…
20 Jul 23
Under the terms of the agreement, Biotheus will grant BioNTech worldwide, exclusive options to a preclinical-stage bispecific antibody…
11 Jul 23
Janssen will obtain an exclusive license to develop and commercialise the NBTXR3 worldwide, in exchange for up to…
11 Jul 23
PRX005 is an anti-tau antibody that specifically targets a region in the microtubule binding region of tau to…
11 Jul 23
Under the agreement, BeiGene will buy an exclusive option for a global clinical and commercial license to DualityBio’s…
11 Jul 23
The objective of the partnership between Evotec and Bristol Myers Squibb is to identify disease-modifying treatments for diverse…
11 Jul 23
Under the terms of the agreement, Doer Bio will grant BioNTech a worldwide license to utilize one of…
06 Jul 23
Under the MOU, both firms will improve Thailand’s capacity for vaccine development and production and will also work…
06 Jul 23
Brii Biosciences has acquired worldwide exclusive license to VBI-2601 and an exclusive license for PreHevbri in the Asia…
30 Jun 23
Under the NEURii collaboration, partners will pool their expertise in therapeutics, technology development and commercialisation, health data management…